FEBS Journal · 2019 · 15 citations · 39 references
MedicineMedicinal ChemistryPharmacologyCarcinogenesisDna RepairMolecular OncologyEnzyme InhibitionTargeted Cancer TherapyAnticancer ActivityChiral Carboxylic AcidsP53 InactivationP53 MutationP53-mediated Dna Repair ControlSubstituent Effects On Biological ActivityTherapeutic Growth InhibitionTumor Suppressor P53
The p53 protein is engaged in the repair of DNA mutations and elimination of heavily damaged cells, providing anticancer protection. Dysregulation of p53 activity is a crucial step in carcinogenesis. This dysregulation is often caused by the overexpression of negative regulators of p53, among which MDM 2 is the most prominent one. Antagonizing MDM 2 with small molecules restores the activity of p53 in p53 wild‐type (p53 wt ) cells and thus provides positive outcomes in the treatment of p53 wt cancers. Previously, we have reported the discovery of a panel of fluoro‐substituted indole‐based antagonists of MDM 2. Here, we demonstrate the biological activity and stereoselectivity of the most active compound from this series. Both enantiomers of the esterified form of the compound, as well as its corresponding carboxylic acids, were found active in fluorescence polarization ( FP ) assay, nuclear magnetic resonance ( NMR ) and microscale thermophoresis ( MST ) assay, with K i and K D values around 1 μ m . From these four compounds, the esterified enantiomer ( R )‐ 5a was active in cells, which was evidenced by the increase of p53 levels, the induced expression of p53‐target genes ( CDKN 1A and MDM 2 ), the selective induction of cell cycle arrest, and selective growth inhibition of p53 wt U‐2 OS and SJSA ‐1 compared to p53 del SAOS ‐2 cells. The analysis of the crystal structure of human MDM 2 in complex with the compound ( R )‐ 6a (carboxylic acid of the active ( R )‐ 5a compound) revealed the classical three‐finger binding mode. Altogether, our data demonstrate the activity of the compound and provide the structural basis for further structure optimization.
39
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text